

## ***What Are the Most Commonly Used NICU Medications and How Dangerous Are They?***

### **References**

Cantey, J. B., Wozniak, P. S., Pruszynski, J. E. & Sánchez, P. J. Reducing unnecessary antibiotic use in the neonatal intensive care unit (SCOUT): a prospective interrupted time-series study. *Lancet Infect Dis* 16, 1178-1184, doi:10.1016/s1473-3099(16)30205-5 (2016).

Fang, P. et al. Prevalence of Multidrug-Resistant Pathogens Causing Neonatal Early and Late Onset Sepsis, a Retrospective Study from the Tertiary Referral Children's Hospital. *Infect Drug Resist* 16, 4213-4225, doi:10.2147/idr.S416020 (2023).

Mukhopadhyay, S. et al. Preterm infants at low risk for early-onset sepsis differ in early fecal microbiome assembly. *Gut Microbes* 14, 2154091, doi:10.1080/19490976.2022.2154091 (2022).

Risnes, K. R., Belanger, K., Murk, W. & Bracken, M. B. Antibiotic exposure by 6 months and asthma and allergy at 6 years: Findings in a cohort of 1,401 US children. *American journal of epidemiology* 173, 310-318, doi:10.1093/aje/kwq400 (2011).

Azad, M. B. & Kozyrskyj, A. L. Perinatal programming of asthma: the role of gut microbiota. *Clin Dev Immunol* 2012, 932072, doi:10.1155/2012/932072 (2012).

Benjamin, D. K., Jr. et al. Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. *JAMA* 311, 1742-1749, doi:10.1001/jama.2014.2624 (2014).

Wade, K. C. et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. *Pediatr Infect Dis J* 28, 717-723, doi:10.1097/INF.0b013e31819f1f50 (2009).

Wade, K. C. et al. Population pharmacokinetics of fluconazole in young infants. *Antimicrobial agents and chemotherapy* 52, 4043-4049, doi:AAC.00569-08 [pii] 10.1128/AAC.00569-08 (2008).

Green, T. P., Thompson, T. R., Johnson, D. E. & Lock, J. E. Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome. *The New England journal of medicine* 308, 743-748, doi:10.1056/nejm198303313081303 (1983).

Brion, L. P. & Campbell, D. E. Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants. *Cochrane Database Syst Rev*, Cd001148, doi:10.1002/14651858.Cd001148 (2001).

Thompson, E. J. et al. Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight. *J Pediatr* 199, 231-236, doi:10.1016/j.jpeds.2018.03.067 (2018).

Heidland, A. & Wigand, M. E. Deafness from furosemide. *Annals of internal medicine* 73, 858, doi:10.7326/0003-4819-73-5-858\_1 (1970).

Schwartz, G. H., David, D. S., Riggio, R. R., Stenzel, K. H. & Rubin, A. L. Ototoxicity induced by furosemide. *The New England journal of medicine* 282, 1413-1414, doi:10.1056/nejm197006182822506 (1970).

Brown, C. B., Ogg, C. S., Cameron, J. S. & Bewick, M. High dose frusemide in acute reversible intrinsic renal failure. A preliminary communication. *Scott Med J* 19 Suppl 1, 35-39, doi:10.1177/00369330740190s108 (1974).

Brummett, R. E., Traynor, J., Brown, R. & Himes, D. Cochlear damage resulting from kanamycin and furosemide. *Acta Otolaryngol* 80, 86-92, doi:10.3109/00016487509121305 (1975).

Borradori, C., Fawer, C. L., Buclin, T. & Calame, A. Risk Factors of Sensorineural Hearing Loss in Preterm Infants. *Neonatology* 71, 1-10, doi:10.1159/000244391 (1997).

Jackson, W. et al. Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review. *Matern Health Neonatol Perinatol* 4, 23, doi:10.1186/s40748-018-0092-2 (2018).

Anand, K. J. et al. Analgesia and sedation in preterm neonates who require ventilatory support: results from the NOPAIN trial. *Neonatal Outcome and Prolonged Analgesia in Neonates. Arch Pediatr Adolesc Med* 153, 331-338, doi:10.1001/archpedi.153.4.331 (1999).

Chrysostomou, C. et al. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. *J Pediatr* 164, 276-282.e271-273, doi:10.1016/j.jpeds.2013.10.002 (2014).

Curtis, S. et al. Use of Dexmedetomidine and Opioids in Hospitalized Preterm Infants. *JAMA Netw Open* 6, e2341033, doi:10.1001/jamanetworkopen.2023.41033 (2023).

Eslami, K., Aletayeb, F., Aletayeb, S. M. H., Kouti, L. & Hardani, A. K. Identifying medication errors in neonatal intensive care units: a two-center study. *BMC pediatrics* 19, 365, doi:10.1186/s12887-019-1748-4 (2019).

Filippone, E. J., Kraft, W. K. & Farber, J. L. The Nephrotoxicity of Vancomycin. *Clinical pharmacology and therapeutics* 102, 459-469, doi:10.1002/cpt.726 (2017).

Goetz, M. B. & Sayers, J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. *J Antimicrob Chemother* 32, 325-334, doi:10.1093/jac/32.2.325 (1993).

Hornik, C. P. et al. Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates. *J Pediatr* 178, 125-129.e121, doi:10.1016/j.jpeds.2016.07.011 (2016).

Kaushal, R. et al. Medication errors and adverse drug events in pediatric inpatients. *Jama* 285, 2114-2120, doi:10.1001/jama.285.16.2114 (2001).

McWilliam, S. J., Antoine, D. J., Smyth, R. L. & Pirmohamed, M. Aminoglycoside-induced nephrotoxicity in children. *Pediatric nephrology (Berlin, Germany)* 32, 2015-2025, doi:10.1007/s00467-016-3533-z (2017).

Menon, G. et al. Morphine analgesia and gastrointestinal morbidity in preterm infants: secondary results from the NEOPAIN trial. *Arch Dis Child Fetal Neonatal Ed* 93, F362-367, doi:10.1136/adc.2007.119297 (2008).

Natarajan, G., Botica, M. L., Thomas, R. & Aranda, J. V. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? *Pediatrics* 119, 936-940, doi:10.1542/peds.2006-2986 (2007).

Polin, R. A. & Carlo, W. A. Surfactant replacement therapy for preterm and term neonates with respiratory distress. *Pediatrics* 133, 156-163, doi:10.1542/peds.2013-3443 (2014).

Portelli, K., Kandraj, H., Ryu, M. & Shah, P. S. Efficacy and safety of dexmedetomidine for analgesia and sedation in neonates: a systematic review. *J Perinatol* 44, 164-172, doi:10.1038/s41372-023-01802-5 (2024).

Raju, T. N. & Langenberg, P. Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis. *J Pediatr* 123, 603-610, doi:10.1016/s0022-3476(05)80963-1 (1993).

Sagheb, S., Mohseni, S. O. & Lamsehchi, A. A new approach to skin extravasation injury management during the neonatal period. *BMC pediatrics* 22, 451, doi:10.1186/s12887-022-03511-y (2022).

Satir, A. N., Pfiffner, M., Meier, C. R. & Caduff Good, A. Prescribing Patterns in Pediatric General Wards and Their Association with Prescribing Errors: A Retrospective Observational Study. *Drugs Real World Outcomes* 10, 619-629, doi:10.1007/s40801-023-00392-0 (2023).

Schmidt, B. et al. Caffeine therapy for apnea of prematurity. *The New England journal of medicine* 354, 2112-2121, doi:10.1056/NEJMoa054065 (2006).

Shaffer, C. L., Davey, A. M., Ransom, J. L., Brown, Y. L. & Gal, P. Ampicillin-induced neurotoxicity in very-low-birth-weight neonates. *The Annals of pharmacotherapy* 32, 482-484, doi:10.1345/aph.17228 (1998).